CD274 and non-small cell lung carcinoma: Presently, the FDA has sanctioned the utilization of three PD-L1 immunohistochemistry (IHC) assays as companion diagnostics: Dako 22C3 (22C3) for Pembrolizumab in patients with diverse solid tumors, including NSCLC; Ventana SP142 (SP142) for Atezolizumab in NSCLC patients; and Dako 28-8 (28-8) for the combination of Ipilimumab and Nivolumab in NSCLC patients (38).